Does oral BPC-157 work?

The one human oral study on record

NCT02637284 is a Phase 1 safety and pharmacokinetics trial sponsored by PharmaCotherapia at Hospital Ángeles Tijuana. The registry describes tablets of PCO-02, each containing 1 mg of BPC-157, given to healthy adults as single doses of 1, 3 or 6 tablets and then as 3 tablets three times daily for 2 weeks, against placebo. ClinicalTrials.gov lists the overall status as unknown, the last known status as active and not recruiting, the record as last verified in October 2015, and no posted results.

For what has been reported about BPC-157's adverse effects, see BPC-157 side effects.

What the rat studies showed

In a 2008 study in the Journal of Pharmacological Sciences, rats with surgically created colon-to-skin fistulas received BPC-157 either in their drinking water or by intraperitoneal injection, and the authors report that it sped fistula healing by either route. The paper calls BPC-157 a "stable gastric pentadecapeptide", the description its originating laboratory uses, and the argument for oral products rests on that stability. Stability in the gut is a different property from absorption into the blood, and no human pharmacokinetic data for oral BPC-157 have been published to show either.

What the human reports used instead

The three published human reports on BPC-157 all used injection or infusion. A 2021 chart review covered 17 patients who received injections into the knee, a 2025 pilot gave intravenous infusions to 2 adults, and a 2024 pilot injected BPC-157 around the bladder wall during cystoscopy in 12 women. None was controlled, and none tested a capsule, tablet or spray.

Nasal and sublingual BPC-157

A PubMed search run for this page on October 7, 2026 found no study of BPC-157 given by nasal, sublingual or buccal routes, in people or in animals. A topical cream has been tested only in mice. For these forms there is no evidence of any kind to report.

What is sold

Of the 71 vendor catalogs Prof. Peptide could read on October 7, 2026, BPC-157 capsules or tablets were listed at 21, BPC-157 sprays at 5, and capsule blends of BPC-157 with TB-500 at 8. These are Prof. Peptide's own counts of research-market listings. None of these products is an approved drug, and no label or study describes how much of any of them is absorbed.